Chimeric antigen receptor (CAR) T cells may have improved therapeutic potential when they have 2 targets, according to preclinical findings using a mouse model.
Adding Temozolomide to Radiotherapy Improves Survival in Elderly Patients With Newly Diagnosed GlioblastomaJune 06, 2016
The addition of temozolomide to standard short-course radiation therapy significantly improved both overall and progression-free survival in elderly patients with newly diagnosed glioblastoma, results from the first study to test this combination in this age group concluded in a plenary presentation at the ASCO 2016 Annual Meeting.
The role of antiangiogenic agents continues to evolve in the treatment of CNS cancers, attendees were told in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.
Abemaciclib, an investigational cancer therapeutic, showed durable clinical activity as a continuous single-agent therapy, according to results of a phase 1 trial with 5 tumor-specific cohorts.
Discovery might eventually lead to better treatment for glioblastoma multiforme
Glioblastoma tumors were successfully infiltrated by investigational CAR therapy with an acceptable safety profile.
The altered metabolism of methionine, tryptophan, kynurenine, and 5-methylthioadenosine can drive the development of glioblastoma. Results also suggest ways to treat the cancer, slow its growth, and precisely elucidate its extent.
Bevacizumab plus irinotecan significantly improved the 6-month progression-free survival (PFS) rate and median progression-free survival.
Progression-free and overall survival were prolonged with electromagnetic field and chemotherapy maintenance therapy in patients with a brain tumor.
Adding tumor-treating fields to maintenance temozolomide chemotherapy significantly prolonged progression-free survival.
Combination Regimen for Recurrent Glioblastoma Improves Progression-free Survival, But Not Overall SurvivalDecember 08, 2015
Bevacizumab treatment combined with lomustine in patients with progressive glioblastoma, despite prolonged progression-free survival, does not confer a survival advantage.
[Clinical Medicine Insights: Oncology] This research examines hypoxia as a new therapeutic target for primary and secondary glioblastomas.
Scientists have discovered how to sensitize drug-resistant human glioblastoma cells to chemotherapy.
Liquid biopsy of cerebrospinal fluid has potential for prognosis, treatment, identification, and tracking of brain tumor genomic alterations both in real time and over time.
An experimental gene therapy essentially doubled the overall survival of patients with recurrent glioblastoma compared with the current standard of care.
The first study to examine the effects of combined radiation and chemotherapy on the healthy brain tissue of glioblastoma patients has revealed specific structural brain changes.
Hampering communication between cancer cells slowed the rapid spread of a common and deadly brain tumor significantly in a mouse model.
Using human tumor samples and mouse models, researchers have found that cancer stem cell properties are determined by epigenetic changes.
Tumors can leverage glucose and acetate to resist targeted therapies directed at specific cellular molecules.
Clinicians testing dasatinib, approved for several blood cancers, were hoping to find that it would slow the growth of glioblastomas.
The adverse event profile of nivolumab with or without ipilimumab in patients with glioblastoma was encouraging.
A combination approach utilizing three differing anticancer drug classes could hold the key to besting glioblastoma.
An innovative pretreatment can enhance the effectiveness of immunotherapy for glioblastoma, dramatically improving patient survival.
Research into the transfer of proteins within the cells of patients with autism has helped broaden our understanding of brain cancer.
A new study has identified three genes that combined enable a lethal form of brain cancer to recur and progress after radiation therapy.
Researchers have found that bevacizumab-induced hypertension may be a predictive marker of improved outcomes in patients with recurrent glioblastoma who are treated with bevacizumab.
New evidence indicates that immune checkpoint inhibitors may work in glioblastoma and brain metastases.
A new drug breakthrough could extend the life of people living with glioblastoma, the most aggressive type of brain cancer.
Researchers have found one key as to why certain glioblastomas are resistant to drug therapy, and the answer lies in a tumor's epigenetic signature.
A triple therapy for glioblastoma, consisting of two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report.
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Recurrence Score Appears To Be Driving Personalized Treatment for Breast Cancer
- Smoking-related Cancer Deaths Highest in Southern United States
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|